195 related articles for article (PubMed ID: 30622514)
1. Parathyroid Apoplexy Following Cinacalcet Treatment in Primary Hyperparathyroidism.
Di Dalmazi G; Giuliani C; Napolitano G
Front Endocrinol (Lausanne); 2018; 9():777. PubMed ID: 30622514
[TBL] [Abstract][Full Text] [Related]
2. Cinacalcet-induced hungry bone syndrome.
Lazar ES; Stankus N
Semin Dial; 2007; 20(1):83-5. PubMed ID: 17244128
[TBL] [Abstract][Full Text] [Related]
3. A Randomized Study Comparing Parathyroidectomy with Cinacalcet for Treating Hypercalcemia in Kidney Allograft Recipients with Hyperparathyroidism.
Cruzado JM; Moreno P; Torregrosa JV; Taco O; Mast R; Gómez-Vaquero C; Polo C; Revuelta I; Francos J; Torras J; García-Barrasa A; Bestard O; Grinyó JM
J Am Soc Nephrol; 2016 Aug; 27(8):2487-94. PubMed ID: 26647424
[TBL] [Abstract][Full Text] [Related]
4. Hypercalcemia of primary hyperparathyroidism was treated by cinacalcet in a patient with liver cirrhosis.
Akinci B; Comlekci A; Tankurt E
Exp Clin Endocrinol Diabetes; 2009 Mar; 117(3):142-5. PubMed ID: 18561096
[TBL] [Abstract][Full Text] [Related]
5. Treatment of Persistent Hypercalcemia and Hyperparathyroidism With Cinacalcet After Successful Kidney Transplantation.
Ważna-Jabłońska E; Gałązka Z; Durlik M
Transplant Proc; 2016 Jun; 48(5):1623-5. PubMed ID: 27496458
[TBL] [Abstract][Full Text] [Related]
6. Cinacalcet: An oral calcimimetic agent for the management of hyperparathyroidism.
Dong BJ
Clin Ther; 2005 Nov; 27(11):1725-51. PubMed ID: 16368445
[TBL] [Abstract][Full Text] [Related]
7. Long-Term Use of Cinacalcet in Kidney Transplant Recipients With Hypercalcemic Secondary Hyperparathyroidism: A Single-Center Prospective Study.
Zavvos V; Fyssa L; Papasotiriou M; Papachristou E; Ntrinias T; Savvidaki E; Goumenos DS
Exp Clin Transplant; 2018 Jun; 16(3):287-293. PubMed ID: 29108515
[TBL] [Abstract][Full Text] [Related]
8. Cinacalcet-Associated Resolution of Primary Hyperparathyroidism in a Patient With Normal Kidney Function.
Nguyen S; Gosmanova EO; Gosmanov AR
J Investig Med High Impact Case Rep; 2020; 8():2324709620936836. PubMed ID: 32583691
[TBL] [Abstract][Full Text] [Related]
9. Incidence, predictors and therapeutic consequences of hypocalcemia in patients treated with cinacalcet in the EVOLVE trial.
Floege J; Tsirtsonis K; Iles J; Drueke TB; Chertow GM; Parfrey P
Kidney Int; 2018 Jun; 93(6):1475-1482. PubMed ID: 29525393
[TBL] [Abstract][Full Text] [Related]
10. Cinacalcet therapy in patients affected by primary hyperparathyroidism associated to Multiple Endocrine Neoplasia Syndrome type 1 (MEN1).
Giusti F; Cianferotti L; Gronchi G; Cioppi F; Masi L; Faggiano A; Colao A; Ferolla P; Brandi ML
Endocrine; 2016 Jun; 52(3):495-506. PubMed ID: 26224587
[TBL] [Abstract][Full Text] [Related]
11. Relationship between parathyroid calcium-sensing receptor expression and potency of the calcimimetic, cinacalcet, in suppressing parathyroid hormone secretion in an in vivo murine model of primary hyperparathyroidism.
Kawata T; Imanishi Y; Kobayashi K; Kenko T; Wada M; Ishimura E; Miki T; Nagano N; Inaba M; Arnold A; Nishizawa Y
Eur J Endocrinol; 2005 Oct; 153(4):587-94. PubMed ID: 16189180
[TBL] [Abstract][Full Text] [Related]
12. The use of cinacalcet hinders the diagnosis of parathyroid carcinoma in a chronic dialysis patient: a case report.
Takada D; Tsukamoto T; Fuse M; Kada S; Yanagita M
BMC Nephrol; 2017 Oct; 18(1):315. PubMed ID: 29047366
[TBL] [Abstract][Full Text] [Related]
13. Clinical utilization of cinacalcet in hypercalcemic conditions.
Messa P; Alfieri C; Brezzi B
Expert Opin Drug Metab Toxicol; 2011 Apr; 7(4):517-28. PubMed ID: 21361849
[TBL] [Abstract][Full Text] [Related]
14. Hypophosphatemia and hungry bone syndrome in a dialysis patient with secondary hyperparathyroidism treated with cinacalcet--proposal for an improved monitoring.
Nowack R; Wachtler P
Clin Lab; 2006; 52(11-12):583-7. PubMed ID: 17175888
[TBL] [Abstract][Full Text] [Related]
15. The calcimimetic cinacalcet normalizes serum calcium in renal transplant patients with persistent hyperparathyroidism.
Kruse AE; Eisenberger U; Frey FJ; Mohaupt MG
Nephrol Dial Transplant; 2005 Jul; 20(7):1311-4. PubMed ID: 15941846
[TBL] [Abstract][Full Text] [Related]
16. Cinacalcet for the treatment of hyperparathyroidism in kidney transplant recipients: a systematic review and meta-analysis.
Cohen JB; Gordon CE; Balk EM; Francis JM
Transplantation; 2012 Nov; 94(10):1041-8. PubMed ID: 23069843
[TBL] [Abstract][Full Text] [Related]
17. Acute presentation of a giant intrathyroidal parathyroid adenoma: a case report.
Rutledge S; Harrison M; O'Connell M; O'Dwyer T; Byrne MM
J Med Case Rep; 2016 Oct; 10(1):286. PubMed ID: 27756436
[TBL] [Abstract][Full Text] [Related]
18. Effect of cinacalcet cessation on hyperparathyroidism in kidney transcaplant patients after long-term dialysis therapy.
Nakai K; Fujii H; Yoshikawa M; Kono K; Yonekura Y; Goto S; Ishimura T; Takeda M; Fujisawa M; Nishi S
Clin Exp Nephrol; 2015 Dec; 19(6):1184-8. PubMed ID: 25782729
[TBL] [Abstract][Full Text] [Related]
19. Cinacalcet is effective in relapses of secondary hyperparathyroidism after parathyroidectomy.
Lomonte C; Antonelli M; Losurdo N; Marchio G; Giammaria B; Basile C
Nephrol Dial Transplant; 2007 Jul; 22(7):2056-62. PubMed ID: 17449495
[TBL] [Abstract][Full Text] [Related]
20. Cinacalcet in the management of primary hyperparathyroidism.
Cetani F; Marcocci C
Expert Rev Endocrinol Metab; 2012 Jan; 7(1):45-53. PubMed ID: 30736110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
